Komori
Soiken Holdings (2385) · RiskRestated

License-Income Risk Relating to Lactoferrin Patent Terms and Sales of Covered Products

First written in FY2018. 14 of 15 entries say "Restated". Latest entry: FY2024-Q2.

15entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2018 – FY2024-Q22018: 220182019: 320192020: 320202021: 220212022: 020222023: 420232024: 1
Same theme, other companies
Uncertainty in License Milestone RevenueA theme 19 companies write about · 19 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2019: 2 of 6 companies on the "Worse" side.

13 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 19 companies compared. The sentences above are computed from all 19.
Full recordFilings, disclosures and news, newest first
  1. FY2024-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  2. FY2024-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  3. FY2023RestatedAnnual report

    「If these patents expire, licensing revenue will cease and the business's sales may decline. In addition, because the amount of licensing revenue is determined by applying a prescribed rate to sales of the covered products sold by the major healthcare company, fluctuations in sales of those products may affect the performance of the business.」

    The risk to licensing revenue arising from the validity period of lactoferrin patents and fluctuations in sales of covered products continues to be disclosed.
  4. FY2023-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  5. FY2023-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  6. FY2022-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  7. FY2021-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  8. FY2021-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  9. FY2020RestatedAnnual report

    「If these patents expire, licensing revenue will cease and the business's sales may decline. In addition, because the amount of licensing revenue is determined by applying a prescribed rate to sales of the covered products sold by the major healthcare company, fluctuations in sales of those products may affect the performance of the business.」

    The risk to licensing revenue arising from the validity period of lactoferrin patents and fluctuations in sales of covered products continues to be disclosed.
  10. FY2020-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  11. FY2020-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  12. FY2019-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated in a consolidated entry that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  13. FY2019-Q2RestatedAnnual report

    「During the six-month period ended [the current second quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated in a consolidated entry that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  14. FY2019-Q1RestatedAnnual report

    「During the three-month period ended [the current first quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    It is stated in a consolidated entry that there have been no material changes in the risk to licensing revenue from the validity period of lactoferrin patents and sales of covered products.
  15. FY2018First statedAnnual report

    「If these patents expire, licensing revenue will cease and the business's sales may decline. In addition, because the amount of licensing revenue is determined by applying a prescribed rate to sales of the covered products sold by the major healthcare company, fluctuations in sales of those products may affect the performance of the business.」

    The disclosure describes the risk of declining licensing revenue due to patent expiration and fluctuations in sales of covered products.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Soiken Holdings yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
License-Income Risk Relating to Lactoferrin Patent Terms and Sales of Covered Products | Soiken Holdings Inc. (2385) | Komori